p 30 kg/m 2 ) In a post hoc analysis, patients randomized to Wegovy HD (N=1,005) had a mean baseline BMI of 2 After 72 weeks on Wegovy HD (N=950), along with diet and exercise, 43.2% reached a BMI vs 8.2% of patients on placebo Limitations 2 : This analysis was not prespecified in the study protocol and was not controlled for multiplicity Post hoc analyses are hypothesis generating and clinical validity cannot be determined # Observed data include only patients who had a body-weight assessment at week 72 (950 of 1,005 for Wegovy HD 7.2 mg injection arm and 171 of 201 for placebo arm) and do not include all randomized patients
thyroid follicular cells) and are regulated by thyroid-stimulating hormone (TSH) made by the thyrotropes of the anterior pituitary gland
A medical-grade abdominal binder may help to reduce the appearance of a C-section pouch
Ten patients received semaglutide 1.0 mg, and one patient each received semaglutide 0.5 mg, liraglutide 1.2 mg and liraglutide 2.4 mg (maximum tolerated dose)
For individuals with alcohol use disorder specifically, additional safety considerations arise
Food and Drug Administration (FDA) approved semaglutide (Wegovy) for chronic weight management in adults with obesity or overweight individuals who have at least one weight-related health condition, such as hypertension, type 2 diabetes, or high cholesterol